101 related articles for article (PubMed ID: 8195023)
1. In vitro cytotoxicity and chemosensitizing activity of the dual function nitroimidazole RB 6145.
Siemann DW
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):301-6. PubMed ID: 8195023
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872.
Siemann DW
Radiother Oncol; 1995 Jan; 34(1):47-53. PubMed ID: 7792398
[TBL] [Abstract][Full Text] [Related]
3. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
Siemann DW
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1115-8. PubMed ID: 2703392
[TBL] [Abstract][Full Text] [Related]
4. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Cole S; Stratford IJ; Adams GE; Fielden EM; Jenkins TC
Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger M; Workman P
Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors.
Siemann DW; Sutherland RM
Radiother Oncol; 1992 Aug; 24(4):239-45. PubMed ID: 1410579
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of dual function nitrofurans in rodent and human tumor cells.
Siemann DW
Int J Radiat Oncol Biol Phys; 1992; 22(4):697-700. PubMed ID: 1544840
[TBL] [Abstract][Full Text] [Related]
8. Studies with bifunctional bioreductive drugs. II. Cytotoxicity assayed with A-549 lung carcinoma cells of human origin.
Roizin-Towle L; Pirro JP; Hall EJ
Radiat Res; 1990 Oct; 124(1 Suppl):S50-5. PubMed ID: 2236511
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
Siemann DW; Alliet K; Maddison K; Wolf K
Cancer Treat Rep; 1985 Dec; 69(12):1409-14. PubMed ID: 3841024
[TBL] [Abstract][Full Text] [Related]
10. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
Hill RP; Gulyas S; Whitmore GF
Br J Cancer; 1986 Jun; 53(6):743-51. PubMed ID: 3755053
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic transforming potential of nitroimidazole radiosensitizers.
Hall EJ; Hei TK
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
[TBL] [Abstract][Full Text] [Related]
12. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Cole S; Stratford IJ; Bowler J; Nolan J; Wright EG; Lorimore SA; Adams GE
Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
[TBL] [Abstract][Full Text] [Related]
13. Studies with bifunctional bioreductive drugs. I. In vitro oncogenic transforming potential.
Hei TK; He ZY; Piao CQ; Hall EJ
Radiat Res; 1990 Oct; 124(1 Suppl):S44-9. PubMed ID: 2236509
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
Siemann DW
Br J Cancer; 1990 Sep; 62(3):348-53. PubMed ID: 2206941
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.
Hay MP; Wilson WR; Moselen JW; Palmer BD; Denny WA
J Med Chem; 1994 Feb; 37(3):381-91. PubMed ID: 8308864
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptake.
Skarsgard LD; Acheson DK; Vinczan A; Wouters BG; Heinrichs BE; Loblaw DA; Minchinton AI; Chaplin DJ
Br J Cancer; 1995 Dec; 72(6):1479-86. PubMed ID: 8519663
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
Hirst DG; Brown JM; Hazlehurst JL
Br J Cancer; 1982 Jul; 46(1):109-16. PubMed ID: 7201845
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
Siemann DW; Maddison K; Wolf K
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of nitroimidazole hypoxic cell radiosensitizers in a human tumor cell line high in intracellular glutathione.
DeGraff WG; Russo A; Gamson J; Mitchell JB
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1021-4. PubMed ID: 2522917
[TBL] [Abstract][Full Text] [Related]
20. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
Siemann DW
Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
